RNU6-310P

Across TCGA pan-cancer cohorts, RNU6-310P RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated RNU6-310P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-310P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-310P expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LIHC, UCEC, and GBM are the cancer types where RNU6-310P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	II,III,IV	0.075	0.431	<.001	87	view →
UCEC	DFS	Tertile	All	0.259	0.651	<.001	54	view →
GBM	OS	Tertile	All	0.076	0.415	<.001	36	view →
CESC	OS	Tertile	All	0.550	0.804	.002	24	view →
KICH	DFS	Tertile	III,IV	0.035	0.772	.021	18	view →
KIRC	DFS	Tertile	IV	0.259	0.617	.011	18	view →
PAAD	DFS	Tertile	All	0.140	0.508	.023	18	view →
LUAD	DFS	Tertile	All	0.649	0.331	.021	15	view →
COAD	OS	Tertile	III,IV	0.208	0.791	.008	9	view →
KIRP	OS	Tertile	All	0.635	0.903	.027	9	view →
SKCM	DFS	Tertile	II,III,IV	0.107	0.317	.048	6	view →
STAD	DFS	Quartile	IV	0.097	0.408	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

RNU6-310P–LIHC (DFS)

Open the LIHC breakdown →